United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 sh

Atwood and Palmer Inc. cut its stake in shares of United Therapeutics Corporation (NASDAQ: UTHR) by

RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and

UTHR tops Q2 EPS estimates, misses revenues, while advancing Tyvaso and ralinepag programs that resh

United Therapeutics NASDAQ: UTHR reported second-quarter 2026 revenue of approximately $783 million,

United Therapeutics Corporation (UTHR) Q2 2026 Earnings Call Transcript

Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business perform

United Therapeutics (UTHR) came out with quarterly earnings of $7.27 per share, beating the Zacks Co

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation

Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR) a

The long-term, pivotal, phase 3 ADVANCE OUTCOMES study of ralinepag in predominantly pre-treated pat

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation

9,500 shares were disposed of for ~$5.0 million based on a weighted average execution price of $530.

Liquidia's Yutrepia launch is fueling rapid growth, outperforming United Therapeutics on estimates a

Atika Capital Management LLC purchased a new stake in shares of United Therapeutics Corporation (NAS

JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and r

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that t

SILVER SPRING, Md. & DURHAM, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR),

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation

PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividen

California Public Employees Retirement System increased its position in shares of United Therapeutic

UTHR's strong clinical wins for Tyvaso and ralinepag, along with progress in organ manufacturing, ar

United Therapeutics is rated a Buy, driven by robust core business growth and a promising late-stage

Dow Jones index up 400 points. IQIYI rose on buyback & HK listing. CODI, UTHR, SGML, CLMT, TRON,

Wall Street opened the week still in negative territory as tensions in the Middle East continued to

US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer

A powerful surge in AI-related stocks — led by a 9% advance in NVIDIA Corp. (NASDAQ:NVDA) over the p

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly ear

Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1

Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (NYSE:EDV) is estimat

Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its

Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for i

  Companies Reporting Before The Bell • Fresh Del Monte Produce (NYSE:FDP) is likely to report qua

  Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report qu

  Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report qu

  Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnin